Through its spin-off program, Helmholtz Enterprise finances the establishment of start-up teams and the implementation of start-up projects in the Helmholtz Association.
Leopard Biosciences GmbH, founded in July, is developing a new diagnostic platform that can detect multiple markers in a single test. The translation of the technology was made possible by funding from the Helmholtz Association.
Ten female-led startups competed in the finale of the Female StartAperitivo startup competition. Ascenion’s portfolio company TimeTeller received the most votes in the public ballot for a method to make chemotherapy more effective and less harmful to the patient.
Ascenion's portfolio company OMEICOS has received a significant grant by the German Federal Ministry of Education and Research (“BMBF”) to co-finance a Phase 2a study evaluating their lead product candidate OMT-28 in Primary Mitochondrial Disease (PMD) patients.
The Berlin start-up develops AI-based software for predicting complications after major cardiac surgery. New business angels and family offices have now invested in the company, alongside the existing investor consortium around IBB Ventures.
The investment round is led by TRUMPF Venture with the objective of translating iThera Medical’s optoacustic imaging technology into routine clinical use.
Recovery Cat has developed software to improve the care of around six million patients in Germany with severe mental disorders. The investors are IBB Ventures’ Impact Fonds, Springboard Health Angels and a family office from Heidelberg.
Bioventure and IFB Innovationsstarter GmbH are financing the Hamburg biotech company for the next four years – to build the necessary infrastructure for research and production.
With the new round of funding, Aignostics aims to continue growing their team, putting a stronger focus on the US market, and accelerating their investment into their platform and regulatory excellence.
Dermagnostix will use the funds to launch its lead product PsorX in Europe and extend its game-changing approach for the molecular diagnosis of skin diseases to further indications.
EUR 47 million committed by fund initiators Ascenion and Goethe-University together with the European Investment Fund (EIF), Evotec, and other investors
Focus on high-potential, early-stage life-science start-ups and projects, sourced from Ascenion’s and Innovectis’ partner institutions and other European academic institutions
15 + 5 years timeframe enables the partners – and the institutions they represent – to participate in future profits
Supported by Ascenion, Felix Krenzien and his team at Charité – Universitätsmedizin Berlin attracted the grant from the Else Kröner-Fresenius-Stiftung (EKFS) to translate their new approach for quantifying extracellular NAD+ into medical practice.
Pharma-backed incubator INCATE selected the HZI start-up project Myxobiotics as one of the first start-ups to get support. Myxobiotics develops a new class of antibiotics against Acinetobacter baumannii, which causes severe, difficult-to-treat respiratory infections.
Supported by Ascenion, Matthias Bruhn and his team at TWINCORE - Centre for Experimental and Clinicial Infection Research have attracted EUR 97,000 to explore the commercial feasibility of their MEMUMAB project. The goal is to provide therapeutic antibodies against infectious diseases such as COVID-19.
The company will use the proceeds to advance its groundbreaking optoacoustic imaging technology into clinical practice. If successful, it would provide a superior, non-invasive alternative to established diagnostic procedures in many diseases.
The German Federal Ministry of Education and Research (BMBF) is providing EUR 6.5 million in funding for 10 selected research projects targeting long-term symptoms of COVID-19. Ascenion’s partner institutes are making significant contributions to three of these projects.
25 August 2021, Munich – Cardior Pharmaceuticals has closed a Series B financing round totalling EUR 64 million (USD 76 million). The round was led by…
The Berlin start-up uses AI to recognize post-operative complications before they become critical. IBB Ventures and several business angels have invested in the company.
As part of its ‘GO-Bio initial’ programme, the BMBF has awarded Ascenion funding for its 'Life Science Digital Hub' concept to improve support for GO-Bio initial applicants.
An innovative approach to combat infections caused by Staphylococcus aureus will receive funding of initially 1.33 million USD plus an additional 7.44 million USD, depending on project progress. It is jointly developed by the HZI and the LDC.
Simultaneously Closes Strategic Growth Investment from Ampersand Capital to Create a Leading Provider of Genomic and Cell and Tissue Analysis Products…
A consortium of nine partners from five European countries, led by the Helmholtz Zentrum München, will work together with a transdisciplinary approach…